БИОХИМИЯ, 2022, том 87, вып. 6, с. 707–726

УДК 577

Помогут ли пептиды остановить Covid‑19?

Обзор

© 2022 В.Г. Круть 1, С.А. Чувпило 1, И.В. Астраханцева 1, Л.И. Козловская 2,3, Г.А. Ефимов 4, А.А. Круглов 5,6,7, М.С. Друцкая 1,8, С.А. Недоспасов 1,5,6,8*sergei.nedospasov@gmail.com

1 АНО ВО Научно-технологический университет Сириус, 354340 Федеральная территория Сириус/Сочи, Россия

2 ФГАНУ «ФНЦИРИП имени М.П. Чумакова РАН», 108819 Москва, Россия

3 Первый Московский государственный медицинский университет имени И.М. Сеченова, Институт трансляционной медицины и биотехнологий, 119991 Москва, Россия

4 Национальный медицинский исследовательский центр гематологии Минздрава России, 125167 Москва, Россия

5 НИИ физико-химической биологии имени А.Н. Белозерского, Московский государственный университет имени М.В. Ломоносова, 119234 Москва, Россия

6 Московский государственный университет имени М.В. Ломоносова, биологический факультет, 119234 Москва, Россия

7 Немецкий исследовательский центр ревматизма (DRFZ), Институт Лейбница, 10117 Берлин, Германия

8 Институт молекулярной биологии имени В.А. Энгельгардта РАН, 119991 Москва, Россия

Поступила в редакцию 31.12.2021
После доработки 24.04.2022
Принята к публикации 11.05.2022

DOI: 10.31857/S0320972522060021

КЛЮЧЕВЫЕ СЛОВА: SARS‑CoV‑2, АСЕ2, вакцина, Т‑клеточные эпитопы.

Аннотация

Пептиды широко применяются в диагностике, профилактике и терапии некоторых заболеваний человека. Насколько они могут быть полезны при болезни, вызываемой коронавирусом SARS‑CoV‑2? В настоящем обзоре мы обсуждаем возможность применения синтетических и рекомбинантных пептидов и полипептидов для профилактики COVID‑19, основанной на блокировке взаимодействия вируса со своим главным рецептором – АСЕ2, а также использование синтетических пептидов в противовирусных вакцинах с учётом возникающих новых вариантов вируса.

Сноски

* Адресат для корреспонденции.

Финансирование

Работа выполнена при финансовой поддержке АНО ВО Научно-технологический университет Сириус (проект № ИМБ‑НИР‑2103), Российского фонда фундаментальных исследований (грант № 20‑04‑60338) и Министерства науки и высшего образования (дополнительное соглашение № 075‑03‑2021‑448/3, тема № 121122300151‑5).

Благодарности

Авторы благодарят А.А. Ишмухаметова за поддержку и интерес к работе, а также Р.А. Абагяна, И.В. Ямпольского и Г.А. Малеева за полезные обсуждения.

Конфликт интересов

Л.И.К. – сотрудник организации ФГАНУ «ФНЦИРИП имени М.П. Чумакова РАН», которая является разработчиком и производителем вакцины против коронавирусной инфекции КовиВак.

Соблюдение этических норм

Настоящая статья не содержит экспериментальных данных, полученных с использованием людей или животных в качестве объектов.

Список литературы

1. Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., and Siddique, R. (2020) COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses, J. Adv. Res., 24, 91-98, doi: 10.1016/j.jare.2020.03.005.

2. Wang, N., Shang, J., Jiang, S., and Du, L. (2020) Subunit vaccines against emerging pathogenic human coronaviruses, Front. Microbiol., 11, 298, doi: 10.3389/fmicb.2020.00298.

3. Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B. J., and Jiang, S. (2009) The spike protein of SARS-CoV — a target for vaccine and therapeutic development, Nat. Rev. Microbiol., 7, 226-236, doi: 10.1038/nrmicro2090.

4. Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270-273, doi: 10.1038/s41586-020-2012-7.

5. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260-1263, doi: 10.1126/science.abb2507.

6. Ortega, J. T., Serrano, M. L., Pujol, F. H., and Rangel, H. R. (2020) Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis, EXCLI J., 19, 410-417, doi: 10.17179/excli2020-1167.

7. Amicone, M., Borges, V., Alves, M. J., Isidro, J., Zé-Zé, L., et al. (2021) Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution, bioRxiv, doi: 10.1101/2021.05.19.444774.

8. Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., et al. (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England, Nature, 593, 266-269, doi: 10.1038/s41586-021-03470-x.

9. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., et al. (2021) SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma, Nat. Med., 27, 622-625, doi: 10.1038/s41591-021-01285-x.

10. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., et al. (2021) Detection of a SARS-CoV-2 variant of concern in South Africa, Nature, 592, 438-443, doi: 10.1038/s41586-021-03402-9.

11. Muik, A., Wallisch, A. K., Sänger, B., Swanson, K. A., Mühl, J., et al. (2021) Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera, Science, 371, 1152-1153, doi: 10.1126/science.abg6105.

12. Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., et al. (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, 372, doi: 10.1126/science.abg3055.

13. Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444-1448, doi: 10.1126/science.abb2762.

14. Belouzard, S., Chu, V. C., and Whittaker, G. R. (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites, Proc. Natl. Acad. Sci. USA, 106, 5871-5876, doi: 10.1073/pnas.0809524106.

15. Barrett, C. T., Neal, H. E., Edmonds, K., Moncman, C. L., Thompson, R., et al. (2021) Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion, J. Biol. Chem., 297, 100902, doi: 10.1016/j.jbc.2021.100902.

16. Singh, J., Rahman, S. A., Ehtesham, N. Z., Hira, S., and Hasnain, S. E. (2021) SARS-CoV-2 variants of concern are emerging in India, Nat. Med., 27, 1131-1133, doi: 10.1038/s41591-021-01397-4.

17. Borisova, N. I., Kotov, I. A., Kolesnikov, A. A., Kaptelova, V. V., Speranskaya, A. S., et al. (2021) Monitoring the spread of the SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) variants in the Moscow region using targeted high-throughput sequencing [in Russia], Vopr. Virusol., 66, 269-278, doi: 10.36233/0507-4088-72.

18. Kumar, S., Thambiraja, T. S., Karuppanan, K., and Subramaniam, G. (2021) Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein, J. Med. Virol., doi: 10.1002/jmv.27526.

19. Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., et al. (2021) Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity, Virology, 563, 134-145, doi: 10.1016/j.virol.2021.09.001.

20. Jhun, H., Park, H. Y., Hisham, Y., Song, C. S., and Kim, S. (2021) SARS-CoV-2 Delta (B. 1.617.2) Variant: A unique T478K mutation in receptor binding motif (RBM) of spike gene, Immune Netw., 21, e32, doi: 10.4110/in.2021.21.e32.

21. Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., et al. (2020) Development of an inactivated vaccine candidate for SARS-CoV-2, Science, 369, 77-81, doi: 10.1126/science.abc1932.

22. Rauch, S., Jasny, E., Schmidt, K. E., and Petsch, B. (2018) New vaccine technologies to combat outbreak situations, Front. Immunol., 9, 1963, doi: 10.3389/fimmu.2018.01963.

23. Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., et al. (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness, Nature, 586, 567-571, doi: 10.1038/s41586-020-2622-0.

24. Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., et al. (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Lancet, 396, 467-478, doi: 10.1016/s0140-6736(20)31604-4.

25. Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., et al. (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia, Lancet, 397, 671-681, doi: 10.1016/s0140-6736(21)00234-8.

26. Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., et al. (2020) A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity, Nature, 586, 572-577, doi: 10.1038/s41586-020-2599-8.

27. Wang, J. (2021) New strategy for COVID-19 vaccination: targeting the receptor-binding domain of the SARS-CoV-2 spike protein, Cell Mol. Immunol., 18, 243-244, doi: 10.1038/s41423-020-00584-6.

28. Tian, J. H., Patel, N., Haupt, R., Zhou, H., Weston, S., et al. (2021) SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice, Nat. Commun., 12, 372, doi: 10.1038/s41467-020-20653-8.

29. Di Natale, C., La Manna, S., De Benedictis, I., Brandi, P., and Marasco, D. (2020) Perspectives in peptide-based vaccination strategies for syndrome coronavirus 2 pandemic, Front. Pharmacol., 11, 578382, doi: 10.3389/fphar.2020.578382.

30. Abduljaleel, Z., Al-Allaf, F. A., and Aziz, S. A. (2021) Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection, Biodes. Manuf., 4, 490-505, doi: 10.1007/s42242-020-00114-3.

31. Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., et al. (2021) A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity, Nature, 601, 617-622, doi: 10.1038/s41586-021-04232-5.

32. Ryzhikov, A. B., Ryzhikov, E. A., Bogryantseva, M. P., Danilenko, E. D., Imatdinov, I. R., et al. (2021) Immunogenicity and protectivity of the Peptide Vaccine against SARS-CoV-2, Ann. Russ. Acad. Med. Sci., 76, 5-19, doi: 10.15690/vramn1528.

33. Ryzhikov, A. B., Ryzhikov, E. A., Bogryantseva, M. P., Usova, S. V., Danilenko, E. D., et al. (2021) A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II), Russ. J. Infect. Immun., 11, 283-296, doi: 10.15789/2220-7619-ASB-1699.

34. Watanabe, M., Omahdi, Z., and Yamasaki, S. (2020) Direct binding analysis between C-type lectins and glycans using immunoglobulin receptor fusion proteins, Methods Mol. Biol., 2132, 119-128, doi: 10.1007/978-1-0716-0430-4_12.

35. Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., et al. (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, 281-292.e286, doi: 10.1016/j.cell.2020.02.058.

36. Tripet, B., Howard, M. W., Jobling, M., Holmes, R. K., Holmes, K. V., et al. (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core, J. Biol. Chem., 279, 20836-20849, doi: 10.1074/jbc.M400759200.

37. Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450-454, doi: 10.1038/nature02145.

38. Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., et al. (2020) Cell entry mechanisms of SARS-CoV-2, Proc. Natl. Acad. Sci. USA, 117, 11727-11734, doi: 10.1073/pnas.2003138117.

39. Hussain, M., Jabeen, N., Amanullah, A., Baig, A. A., Aziz, B., et al. (2020) Structural basis of SARS-CoV-2 spike protein priming by TMPRSS2, bioRxiv, doi: 10.1101/2020.04.21.052639.

40. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271-280.e278, doi: 10.1016/j.cell.2020.02.052.

41. VanPatten, S., He, M., Altiti, A., Cheng, K. F., Ghanem, M. H., et al. (2020) Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics, Future Med. Chem., 12, 1647-1656, doi: 10.4155/fmc-2020-0180.

42. Hamming, I., Timens, W., Bulthuis, M. L., Lely, A. T., Navis, G., et al. (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol., 203, 631-637, doi: 10.1002/path.1570.

43. Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., et al. (2020) Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2, Am. J. Respir. Crit. Care Med., 202, 756-759, doi: 10.1164/rccm.202001-0179LE.

44. Millet, J. K., and Whittaker, G. R. (2015) Host cell proteases: critical determinants of coronavirus tropism and pathogenesis, Virus Res., 202, 120-134, doi: 10.1016/j.virusres.2014.11.021.

45. Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S., et al. (2011) A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry, J. Virol., 85, 873-882, doi: 10.1128/jvi.02062-10.

46. Chambers, J. P., Yu, J., Valdes, J. J., and Arulanandam, B. P. (2020) SARS-CoV-2, early entry events, J. Pathog., 2020, 9238696, doi: 10.1155/2020/9238696.

47. Gur, M., Taka, E., Yilmaz, S. Z., Kilinc, C., Aktas, U., et al. (2020) Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states, J. Chem. Phys., 153, 075101, doi: 10.1063/5.0011141.

48. Xu, C., Wang, Y., Liu, C., Zhang, C., Han, W., et al. (2021) Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM, Sci. Adv., 7, doi: 10.1126/sciadv.abe5575.

49. Jackson, C. B., Farzan, M., Chen, B., and Choe, H. (2022) Mechanisms of SARS-CoV-2 entry into cells, Nat. Rev. Mol. Cell Biol., 23, 3-20, doi: 10.1038/s41580-021-00418-x.

50. Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R., and Daniel, S. (2020) Coronavirus membrane fusion mechanism offers a potential target for antiviral development, Antiviral. Res., 178, 104792, doi: 10.1016/j.antiviral.2020.104792.

51. Bosch, B. J., van der Zee, R., de Haan, C. A., and Rottier, P. J. (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex, J. Virol., 77, 8801-8811, doi: 10.1128/jvi.77.16.8801-8811.2003.

52. White, J. M., Delos, S. E., Brecher, M., and Schornberg, K. (2008) Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme, Crit. Rev. Biochem. Mol. Biol., 43, 189-219, doi: 10.1080/10409230802058320.

53. Millet, J. K., and Whittaker, G. R. (2018) Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells, Virology, 517, 3-8, doi: 10.1016/j.virol.2017.12.015.

54. Chen, Y., Guo, Y., Pan, Y., and Zhao, Z. J. (2020) Structure analysis of the receptor binding of 2019-nCoV, Biochem. Biophys. Res. Commun., 525, 135-140, doi: 10.1016/j.bbrc.2020.02.071.

55. Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., et al. (2020) Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein, Cell. Mol. Immunol., 17, 765-767, doi: 10.1038/s41423-020-0374-2.

56. Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., et al. (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion, Cell Res., 30, 343-355, doi: 10.1038/s41422-020-0305-x.

57. Smyth, M. S., and Martin, J. H. (2000) X Ray crys­tallography, Mol. Pathol., 53, 8-14, doi: 10.1136/mp.53.1.8.

58. Smith, G. P. (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science, 228, 1315-1317, doi: 10.1126/science.4001944.

59. Trier, N. H., Hansen, P. R., and Houen, G. (2012) Production and characterization of peptide antibodies, Methods, 56, 136-144, doi: 10.1016/j.ymeth.2011.12.001.

60. Lee, A. C., Harris, J. L., Khanna, K. K., and Hong, J. H. (2019) A comprehensive review on current advances in peptide drug development and design, Int. J. Mol. Sci., 20, doi: 10.3390/ijms20102383.

61. Rabinowitz, J. A., Lainson, J. C., Johnston, S. A., and Diehnelt, C. W. (2018) Non-natural amino acid peptide microarrays to discover Ebola virus glycoprotein ligands, Chem. Commun., 54, 1417-1420, doi: 10.1039/c7cc08242h.

62. Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y. J., Hrin, R., et al. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency, Proc. Natl. Acad. Sci. USA, 106, 5801-5806, doi: 10.1073/pnas.0901007106.

63. Pessi, A., Bixler, S. L., Soloveva, V., Radoshitzky, S., Retterer, C., et al. (2019) Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo, Antiviral Res., 171, 104592, doi: 10.1016/j.antiviral.2019.104592.

64. Chen, G., Cook, J. D., Ye, W., Lee, J. E., and Sidhu, S. S. (2019) Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display, Protein Sci., 28, 1501-1512, doi: 10.1002/pro.3669.

65. Ding, X., Zhang, X., Chong, H., Zhu, Y., Wei, H., Wu, X., et al. (2017) Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: Implications for viral entry and inhibition, J. Virol., 91, doi: 10.1128/jvi.00831-17.

66. Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., et al. (2010) Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy, J. Med. Chem., 53, 4441-4449, doi: 10.1021/jm1002183.

67. Kadam, R. U., Juraszek, J., Brandenburg, B., Buyck, C., Schepens, W. B. G., et al. (2017) Potent peptidic fusion inhibitors of influenza virus, Science, 358, 496-502, doi: 10.1126/science.aan0516.

68. Shilovskiy, I. P., Andreev, S. M., Kozhikhova, K. V., Nikolskii, A. A., and Khaitov, M. R. (2019) Prospects for the use of peptides against respiratory syncytial virus [in Russian], Mol. Biol. (Mosk), 53, 541-560, doi: 10.1134/s002689841904013x.

69. Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., et al. (2020) Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability, Science, 369, 643-650, doi: 10.1126/science.abc5902.

70. Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A., et al. (2020) A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, doi: 10.1038/s41467-020-16256-y.

71. Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., et al. (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA, 101, 2536-2541, doi: 10.1073/pnas.0307140101.

72. Walls, A. C., Xiong, X., Park, Y. J., Tortorici, M. A., Snijder, J., et al. (2019) Unexpected receptor functional mimicry elucidates activation of coronavirus fusion, Cell, 176, 1026-1039.e1015, doi: 10.1016/j.cell.2018.12.028.

73. Khavinson, V., Linkova, N., Dyatlova, A., Kuznik, B., and Umnov, R. (2020) Peptides: prospects for use in the treatment of COVID-19, Molecules, 25, doi: 10.3390/molecules25194389.

74. Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat. Med., 11, 875-879, doi: 10.1038/nm1267.

75. Mantovani, A., Locati, M., Vecchi, A., Sozzani, S., and Allavena, P. (2001) Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines, Trends Immunol., 22, 328-336, doi: 10.1016/s1471-4906(01)01941-x.

76. Dinarello, C. A. (1997) Interleukin-1, Cytokine Growth Factor Rev., 8, 253-265, doi: 10.1016/s1359-6101(97)00023-3.

77. Idriss, H. T., and Naismith, J. H. (2000) TNF alpha and the TNF receptor superfamily: structure-function relationship(s), Microsc Res. Tech., 50, 184-195, doi: 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.

78. Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., et al. (2020) Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 290-295, doi: 10.1038/s41586-020-2349-y.

79. Zoufaly, A., Poglitsch, M., Aberle, J. H., Hoepler, W., Seitz, T., et al. (2020) Human recombinant soluble ACE2 in severe COVID-19, Lancet Respir. Med., 8, 1154-1158, doi: 10.1016/s2213-2600(20)30418-5.

80. Chan, K. K., Dorosky, D., Sharma, P., Abbasi, S. A., Dye, J. M., et al. (2020) Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2, Science, 369, 1261-1265, doi: 10.1126/science.abc0870.

81. Lu, J., and Sun, P. D. (2020) High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity, bioRxiv, doi: 10.1101/2020.07.01.182659.

82. Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., et al. (2020) Engineered ACE2 receptor traps potently neutralize SARS-CoV-2, bioRxiv, doi: 10.1101/2020.07.31.231746.

83. Chan, K. K., Tan, T. J. C., Narayanan, K. K., and Procko, E. (2020) An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants, bioRxiv, doi: 10.1101/2020.10.18.344622.

84. Zhang, G., Pomplun, S., Loftis, A. R., Tan, X., Loas, A., et al. (2020), Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD, bioRxiv, doi: 10.1101/2020.03.19.999318.

85. Karoyan, P., Vieillard, V., Gómez-Morales, L., Odile, E., Guihot, A., et al. (2021) Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection, Commun. Biol., 4, 197, doi: 10.1038/s42003-021-01736-8.

86. Rezaei Araghi, R., and Keating, A. E. (2016) Designing helical peptide inhibitors of protein-protein interactions, Curr. Opin. Struct. Biol., 39, 27-38, doi: 10.1016/j.sbi.2016.04.001.

87. Ali, A. M., Atmaj, J., Van Oosterwijk, N., Groves, M. R., and Dömling, A. (2019) Stapled peptides inhibitors: A new window for target drug discovery, Comput. Struct. Biotechnol. J., 17, 263-281, doi: 10.1016/j.csbj.2019.01.012.

88. Morgan, D. C., Morris, C., Mahindra, A., Blair, C. M., Tejeda, G., et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization, Pept. Sci. (Hoboken), e24217, doi: 10.1002/pep2.24217.

89. Curreli, F., Victor, S. M. B., Ahmed, S., Drelich, A., Tong, X., et al. (2020) Stapled Peptides based on human angiotensin-converting enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro, mBio, 11, doi: 10.1128/mBio.02451-20.

90. Bibilashvili, R. S., Sidorova, M. V., Dudkina, U. S., Palkeeva, M. E., Molokoedov, A. S., et al. (2021) Peptide inhibitors of the interaction of the SARS-CoV-2 receptor-binding domain with the ACE2 cell receptor, Biochem. Mosc. Suppl. B Biomed. Chem., 15, 274-280, doi: 10.1134/s199075082104003x.

91. Krut, V. G., Astrakhantseva, I. V., Chuvpilo, S. A., Efimov, G. A., Ambaryan, S. G., et al. (2021) Antibodies to the N-terminal domain of angiotensin-converting enzyme (ACE2) that block its interaction with SARS-CoV-2 S protein, Dokl. Biochem. Biophys., 4, 1-4, doi: 10.1134/S160767292201001X.

92. Larue, R. C., Xing, E., Kenney, A. D., Zhang, Y., Tuazon, J. A., et al. (2021) Rationally designed ACE2-derived peptides inhibit SARS-CoV-2, Bioconjug. Chem., 32, 215-223, doi: 10.1021/acs.bioconjchem.0c00664.

93. Adhikary, P., Kandel, S., Mamani, U. F., Mustafa, B., Hao, S., et al. (2021) Discovery of small anti-ACE2 peptides to inhibit SARS-CoV-2 infectivity, Adv. Ther. (Weinh), 2100087, doi: 10.1002/adtp.202100087.

94. Wettstein, L., Kirchhoff, F., and Münch, J. (2022) The transmembrane protease TMPRSS2 as a therapeutic target for COVID-19 treatment, Int. J. Mol. Sci., 23, 1351, doi: 10.3390/ijms23031351.

95. Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., et al. (2019) TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after Coronavirus infection, J. Virol., 93, doi: 10.1128/jvi.01815-18.

96. Lucas, J. M., Heinlein, C., Kim, T., Hernandez, S. A., Malik, M. S., et al. (2014) The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis, Cancer Discov., 4, 1310-1325, doi: 10.1158/2159-8290.Cd-13-1010.

97. Bertram, S., Glowacka, I., Blazejewska, P., Soilleux, E., Allen, P., et al. (2010) TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells, J. Virol., 84, 10016-10025, doi: 10.1128/jvi.00239-10.

98. Böttcher-Friebertshäuser, E., Freuer, C., Sielaff, F., Schmidt, S., et al. (2010) Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors, J. Virol., 84, 5605-5614, doi: 10.1128/jvi.00140-10.

99. Bittle, J. L., Houghten, R. A., Alexander, H., Shinnick, T. M., Sutcliffe, J. G., et al. (1982) Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence, Nature, 298, 30-33, doi: 10.1038/298030a0.

100. Langeveld, J. P., Casal, J. I., Osterhaus, A. D., Cortés, E., de Swart, R., et al. (1994) First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs, J. Virol., 68, 4506-4513, doi: 10.1128/JVI.68.7.4506-4513.1994.

101. Casal, J. I., Langeveld, J. P., Cortés, E., Schaaper, W. W., van Dijk, E., et al. (1995) Peptide vaccine against canine parvovirus: Identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence, J. Virol., 69, 7274-7277, doi: 10.1128/JVI.69.11.7274-7277.1995.

102. DiMarchi, R., Brooke, G., Gale, C., Cracknell, V., Doel, T., et al. (1986) Protection of cattle against foot-and-mouth disease by a synthetic peptide, Science, 232, 639-641, doi: 10.1126/science.3008333.

103. Broekhuijsen, M. P., van Rijn, J. M., Blom, A. J., Pouwels, P. H., Enger-Valk, B. E., et al. (1987) Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals, J. Gen. Virol., 68, 3137-3143, doi: 10.1099/0022-1317-68-12-3137.

104. Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., et al. (2020) Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity, Cell, 183, 996-1012.e1019, doi: 10.1016/j.cell.2020.09.038.99.

105. Rammensee, H. G., Wiesmüller, K. H., Chandran, P. A., Zelba, H., Rusch, E., et al. (2019) A new syn­thetic toll-like receptor 1/2 ligand is an efficient adju­vant for peptide vaccination in a human volunteer, J. Immunother Cancer, 7, 307, doi: 10.1186/s40425-019-0796-5.102.

106. Nelde, A., Bilich, T., Heitmann, J. S., Maringer, Y., Salih, H. R., et al. (2021) SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition, Nat. Immunol., 22, 74-85, doi: 10.1038/s41590-020-00808-x.

107. Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., et al. (2021) T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals, Sci. Transl. Med., 13, doi: 10.1126/scitranslmed.abf7517.

108. Barchuk, A., Cherkashin, M., Bulina, A., Berezina, N., Rakova, T., et al. (2021) Vaccine effectiveness against referral to hospital and severe lung injury associated with COVID-19: a population-based case-control study in St. Petersburg, Russia, medRxiv, doi: 10.1101/2021.08.18.21262065.

109. Shomuradova, A. S., Vagida, M. S., Sheetikov, S. A., Zornikova, K. V., Kiryukhin, D., et al. (2020) SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors, Immunity, 53, 1245-1257.e1245, doi: 10.1016/j.immuni.2020.11.004.

110. Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M. V., Weinheimer, A., et al. (2020) Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein, Immunity, 53, 1095-1107.e1093, doi: 10.1016/j.immuni.2020.10.006.

111. Titov, A., Shaykhutdinova, R., Shcherbakova, O. V., Serdyuk, Y. V., Sheetikov, S. A., et al. (2022) Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2, JCI Insight, doi: 10.1172/jci.insight.157699.